Spruce Biosciences Delays TA-ERT BLA Submission to Q4 2026 After Positive FDA Meetings

Event summary

  • Spruce Biosciences completed Type B meetings with the FDA regarding its planned BLA submission for TA-ERT, pushing the submission timeline to Q4 2026.
  • FDA confirmed that integrated study data and natural history data could potentially serve as an adequate and well-controlled study for TA-ERT's review.
  • FDA required one drug product (DP) process performance qualification (PPQ) batch at BLA submission and a second DP PPQ batch prior to midcycle of BLA review.
  • TA-ERT has Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations from the FDA for treating Sanfilippo Syndrome Type B (MPS IIIB).

The big picture

Spruce Biosciences' positive Type B meetings with the FDA mark a critical step in the regulatory pathway for TA-ERT, a potential first-of-its-kind treatment for Sanfilippo Syndrome Type B. The delay in BLA submission to Q4 2026 reflects the FDA's stringent requirements but also underscores the agency's constructive engagement. The reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program adds a strategic incentive for rare disease therapies, positioning TA-ERT within a broader industry trend toward accelerated approvals for ultra-rare conditions.

What we're watching

Regulatory Clarity
How the FDA's acceptance of CSF HS-NRE as a reasonably likely surrogate endpoint will impact the BLA review process.
Execution Risk
Whether Spruce Biosciences can meet the FDA's PPQ batch requirements and initiate the confirmatory study during BLA review.
Market Positioning
The pace at which TA-ERT can position itself as the first disease-modifying treatment for MPS IIIB if approved.